Dialysis world news


NxStage Medical Rating Lowered to Hold at Zacks (NXTM) - Dakota Financial News PDF Print

NxStage Medical (NASDAQ:NXTM) was downgraded by Zacks from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Market Beat reports.

According to Zacks, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. “

Separately, TheStreet cut NxStage Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, July 8th.

In other news, SVP Winifred L. Swan sold 2,500 shares of NxStage Medical stock in a transaction dated Tuesday, July 14th. The stock was sold at an average price of $14.71, for a total value of $36,775.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Joseph E. Turk, Jr. sold 2,000 shares of NxStage Medical stock in a transaction dated Wednesday, July 22nd. The stock was sold at an average price of $13.86, for a total value of $27,720.00. The disclosure for this sale can be found here.

NxStage Medical (NASDAQ:NXTM) traded down 0.21% during midday trading on Thursday, hitting $13.99. The company had a trading volume of 441,493 shares. The company’s 50 day moving average is $14.65 and its 200-day moving average is $16.84. NxStage Medical has a one year low of $13.83 and a one year high of $14.18. The company’s market cap is $884.70 million.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings data on Wednesday, May 6th. The medical device company reported ($0.09) EPS for the quarter, topping the analysts’ consensus estimate of ($0.11) by $0.02. The company had revenue of $79.50 million for the quarter, compared to analyst estimates of $77.92 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. NxStage Medical’s revenue was up 10.1% compared to the same quarter last year. On average, equities analysts predict that NxStage Medical will post ($0.36) EPS for the current year.

NxStage Medical, Inc. (NASDAQ:NXTM)is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). The Company operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it sells and rents the System One, PureFlow SL equipment and disposable products in the home and critical care markets. In the In-Center segment, it sells of blood tubing sets and needles for hemodialysis at dialysis centers and needles for apheresis. The Company’s products include the NxStage System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.image

To get a free copy of the research report on NxStage Medical (NXTM), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

...

 
3 Stocks Pushing The Health Care Sector Lower - TheStreet.com PDF Print

3 Stocks Pushing The Health Care Sector Lower
TheStreet.com
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease (ESRD); and other health care services. Fresenius Medical Care AG & Co.

and more »

...

 
Fresenius Medical Care AG Co. (FMS) Posts Earnings Results, Beats Estimates ... - Dakota Financial News PDF Print

Fresenius Medical Care AG & Co. (NYSE:FMS) released its quarterly earnings data on Thursday. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.43 by $0.36, Analyst Ratings Net reports. The business earned $4.20 billion during the quarter, compared to analysts’ expectations of $4.13 billion. The company’s quarterly revenue was up 15.0% on a year-over-year basis.

Fresenius Medical Care AG & Co. (NYSE:FMS) traded down 4.87% on Thursday, reaching $41.06. The company had a trading volume of 358,442 shares. Fresenius Medical Care AG & Co. has a 12 month low of $32.40 and a 12 month high of $44.34. The stock has a 50 day moving average of $42.66 and a 200 day moving average of $41.17. The firm has a market capitalization of $24.96 billion and a PE ratio of 23.75.

Separately, Commerzbank AG downgraded Fresenius Medical Care AG & Co. to a “hold” rating in a research note on Friday, May 29th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $37.03.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.image

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...

 
Dialysis patient thankful for new Souris unit - CBC.ca PDF Print

The new $300,000 dialysis unit at the Souris Hospital is not only more convenient for patient Nathan Bushey, it feels like a second home.

Three days a week Bushey, who is from Souris, spends four hours at a time receiving dialysis treatment. He calls it a full-time part-time job.

After the unit closed in 2014 due to water filtration system problems, Bushey and the other Souris dialysis patients were forced to travel to Charlottetown for treatment for nine months.

But after the community rallied, the new state-of-the-art unit was built.

It opened in March and will expand later this year to accommodate up to 12 patients a week.

Bushey describes how the unit has improved the quality of his treatment — and his life.

...

 
Renal Ventures Expands Services to Flower Mound, Texas - Business Wire (press release) PDF Print

LAKEWOOD, Colo.--(BUSINESS WIRE)--Renal Ventures Management, LLC (RVM), a leading provider of dialysis services for patients suffering from end-stage renal disease (ESRD), completed construction of a new hemodialysis center in Flower Mound, Texas, and opened its doors to patients on July 8. Partnering with North Texas Kidney Disease Associates (NTKDA) to decide on a suitable location for the new center, RVM began construction of the Renal Center of Flower Mound in January 2015.

The Renal Center of Flower Mound, LLC features 13 heated hemodialysis chairs with free WI-FI, personal TVs and a café with coffee for patients. Operating under the supervision of Clinic Coordinator Marissa Dunlap, the center is currently accepting new hemodialysis patients looking for a comfortable, inviting treatment facility.

"We are excited to work with the community of Flower Mound, Texas, by providing high quality dialysis services in this beautiful, state-of-the-art center," said Renal Ventures Management Divisional Director, Tammy Jensen.

The opening of the center has been a well-coordinated effort among senior management, the operations department and third-party companies. The building also includes adjoining office space for the NTKDA nephrology practice.

At the Renal Center of Flower Mound, RVM implemented all of its quality programs, which continue to provide positive outcomes for patients. The programs include the RV Difference™, the framework for RVM's company culture; RV CARE™, which helps patients successfully transition to dialysis during the first 120 days; and RV Kidney Care, which provides ongoing education and support to chronic kidney disease patients.

The Renal Center of Flower Mound is located at 4941 Long Prairie Road, Flower Mound, TX 75028 and on the Web at www.renalcenterofflowermound.com.

About Renal Ventures Management, LLC

Renal Ventures Management LLC is a leading provider of dialysis services in the U.S. The company partners with hospitals and physicians to provide patients suffering from chronic kidney failure with knowledgeable, compassionate and quality-focused care in comfortable clinic settings. For its hospital and nephrologist partners, Renal Ventures Management provides management expertise and patient-focused care operations that center on collaboration, quality and effectiveness. Headquartered in Lakewood, Colo., the company operates 36 dialysis partnerships and 26 inpatient service contracts in six states. They also operate seven infusion centers in two states treating patients with various autoimmune disorders and a vascular access center in Lafayette, Louisiana. For more information, visit www.renalventures.com.

...

 
<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>

Page 30 of 2630
Share |
Copyright © 2017 Global Dialysis. All Rights Reserved.